METHOD OF INCREASING TEAR PRODUCTION WITH PURINERGIC RECEPTOR AGONISTS
    1.
    发明申请
    METHOD OF INCREASING TEAR PRODUCTION WITH PURINERGIC RECEPTOR AGONISTS 有权
    增加与纯化受体激动剂进行生产的方法

    公开(公告)号:US20100330164A1

    公开(公告)日:2010-12-30

    申请号:US12825051

    申请日:2010-06-28

    摘要: A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucleotides, cytidine 5′-triphosphate (CTP), adenosine 5′-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.

    摘要翻译: 公开了用于刺激需要这种治疗的受试者的泪液分泌的方法和制剂。 该方法包括向受试者的眼表面施用嘌呤能受体激动剂如尿苷5'-三磷酸(UTP),二核苷酸,胞苷5'-三磷酸(CTP),腺苷5'-三磷酸(ATP)或其治疗上有用的 类似物和衍生物,其量有效地刺激泪液分泌并增强泪液系统的引流。 还公开了药物制剂及其制备方法。 施用该方法的方法将包括:通过液体,凝胶,霜剂或作为隐形眼镜或选择性释放膜的一部分局部给药; 或通过鼻滴或喷雾进行全身给药,通过喷雾器或其它装置吸入,口服形式(液体或丸剂),可注射的,术中滴注或栓剂形式。

    Method of treating dry eye disease with purinergic receptor agonists
    2.
    发明授权
    Method of treating dry eye disease with purinergic receptor agonists 有权
    用嘌呤能受体激动剂治疗干眼病的方法

    公开(公告)号:US07759322B2

    公开(公告)日:2010-07-20

    申请号:US11821091

    申请日:2007-06-20

    IPC分类号: A01N43/04 A61K31/70

    摘要: A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucleotides, cytidine 5′-triphosphate (CTP), adenosine 5′-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.

    摘要翻译: 公开了用于刺激需要这种治疗的受试者的泪液分泌的方法和制剂。 该方法包括向受试者的眼表面施用嘌呤能受体激动剂如尿苷5'-三磷酸(UTP),二核苷酸,胞苷5'-三磷酸(CTP),腺苷5'-三磷酸(ATP)或其治疗上有用的 类似物和衍生物,其量有效地刺激泪液分泌并增强泪液系统的引流。 还公开了药物制剂及其制备方法。 施用该方法的方法将包括:通过液体,凝胶,霜剂或作为隐形眼镜或选择性释放膜的一部分局部给药; 或通过鼻滴或喷雾进行全身给药,通过喷雾器或其它装置吸入,口服形式(液体或丸剂),可注射的,术中滴注或栓剂形式。

    Method of treating dry eye disease with purinergic receptor agonists
    5.
    发明授权
    Method of treating dry eye disease with purinergic receptor agonists 有权
    用嘌呤能受体激动剂治疗干眼病的方法

    公开(公告)号:US06921755B2

    公开(公告)日:2005-07-26

    申请号:US10010055

    申请日:2001-11-09

    IPC分类号: A61K45/06 A61K31/70

    CPC分类号: A61K45/06 Y10S514/912

    摘要: A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucleotides, cytidine 5′-triphosphate (CTP), adenosine 5′-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.

    摘要翻译: 公开了用于刺激需要这种治疗的受试者的泪液分泌的方法和制剂。 该方法包括向受试者的眼表面施用嘌呤能受体激动剂如尿苷5'-三磷酸(UTP),二核苷酸,胞苷5'-三磷酸(CTP),腺苷5'-三磷酸(ATP)或其治疗上有用的 类似物和衍生物,其量有效地刺激泪液分泌并增强泪液系统的引流。 还公开了药物制剂及其制备方法。 施用该方法的方法将包括:通过液体,凝胶,霜剂或作为隐形眼镜或选择性释放膜的一部分局部给药; 或通过鼻滴或喷雾进行全身给药,通过喷雾器或其它装置吸入,口服形式(液体或丸剂),可注射的,术中滴注或栓剂形式。

    Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
    6.
    发明授权
    Method of treating ciliary dyskinesia with uridine triphosphates and related compounds 失效
    用尿苷三磷酸和相关化合物治疗睫状肌运动障碍的方法

    公开(公告)号:US06420347B1

    公开(公告)日:2002-07-16

    申请号:US09101840

    申请日:1998-07-17

    IPC分类号: A61K3170

    CPC分类号: A61K31/70

    摘要: A method of stimulating ciliary beat frequency in a subject in need of such treatment is disclosed. The method comprises administering to the airways, ears, eyes, or genito-urinary tract of the subject a triphosphate nucleotide such as uridine 5′-triphosphate (UTP), an analog of UTP, or any other analog, in an amount effective to stimulate ciliary beat frequency. This method is useful for treating patients afflicted with ciliary dyskinesia, Kartagener's syndrome, or any other disease involving dysfunction of ciliary movement, such as male infertility caused by impairment of propulsion of the spermatozoa or immune deficiency caused by impairment of ciliary movement in neutrophils or macrophages. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include any liquid suspension (including nasal spray or nasal or eye drops), oral, inhaled by nebulization, topical, injected, suppository, intra-operative by instillation or application, or ex vivo direct application to spermatozoa.

    摘要翻译: 公开了一种在需要这种治疗的受试者中刺激睫状肌搏动频率的方法。 该方法包括向受试者的气道,耳朵,眼睛或生殖泌尿道施用有效刺激的量的三磷酸核苷酸,例如尿苷5'-三磷酸(UTP),UTP类似物或任何其它类似物 睫毛拍频。 该方法可用于治疗患有睫状肌运动障碍,Kartagener综合征或涉及睫状肌运动功能障碍的任何其他疾病,例如由嗜中性粒细胞或巨噬细胞的睫状肌运动损伤引起的精子推进或免疫缺陷引起的男性不育症 。 还公开了药物制剂及其制备方法。 给药方法包括任何液体悬浮液(包括鼻喷雾或鼻腔或滴眼液),口服,通过雾化吸入,局部注射,注射,栓剂,通过滴注或施用手术,或离体直接施用于精子。

    Method of increasing tear production with purinergic receptor agonists
    7.
    发明授权
    Method of increasing tear production with purinergic receptor agonists 有权
    用嘌呤能受体激动剂增加泪液产生的方法

    公开(公告)号:US08097600B2

    公开(公告)日:2012-01-17

    申请号:US12825051

    申请日:2010-06-28

    IPC分类号: A01N43/04 A61K31/70

    摘要: A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucleotides, cytidine 5′-triphosphate (CTP), adenosine 5′-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.

    摘要翻译: 公开了用于刺激需要这种治疗的受试者的泪液分泌的方法和制剂。 该方法包括向受试者的眼表面施用嘌呤能受体激动剂如尿苷5'-三磷酸(UTP),二核苷酸,胞苷5'-三磷酸(CTP),腺苷5'-三磷酸(ATP)或其治疗上有用的 类似物和衍生物,其量有效地刺激泪液分泌并增强泪液系统的引流。 还公开了药物制剂及其制备方法。 施用该方法的方法将包括:通过液体,凝胶,霜剂或作为隐形眼镜或选择性释放膜的一部分局部给药; 或通过鼻滴或喷雾进行全身给药,通过喷雾器或其它装置吸入,口服形式(液体或丸剂),可注射的,术中滴注或栓剂形式。

    Method of enhancing drainage of lacrimal system with purinergic receptor agonists
    9.
    发明授权
    Method of enhancing drainage of lacrimal system with purinergic receptor agonists 有权
    用嘌呤能受体激动剂增强泪液排出的方法

    公开(公告)号:US07235535B2

    公开(公告)日:2007-06-26

    申请号:US11114957

    申请日:2005-04-25

    摘要: A method and preparation for enhancing drainage of lacrimal system in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucleotides, cytidine 5′-triphosphate (CTP), adenosine 5′-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.

    摘要翻译: 公开了一种用于增强需要这种治疗的受试者中泪液系统排泄的方法和制备方法。 该方法包括向受试者的眼表面施用嘌呤能受体激动剂如尿苷5'-三磷酸(UTP),二核苷酸,胞苷5'-三磷酸(CTP),腺苷5'-三磷酸(ATP)或其治疗上有用的 类似物和衍生物,其量有效地刺激泪液分泌并增强泪液系统的引流。 还公开了药物制剂及其制备方法。 施用该方法的方法将包括:通过液体,凝胶,霜剂或作为隐形眼镜或选择性释放膜的一部分局部给药; 或通过鼻滴或喷雾进行全身给药,通过喷雾器或其它装置吸入,口服形式(液体或丸剂),可注射的,术中滴注或栓剂形式。